Enter inventor name

Chad Dickey

USPTO Granted Patents = 16 (Patent Applications = 5)

Average Co-Inventor Count = 3.1

ph-index = 2

Forward Citations = 8(Granted Patents)

Location History:

Lutz, FL (US) (2019)
Tampa, FL (US) (2015 - 2024)

Company Filing History:

16 out of 1,933

University of South Florida

The United States Government As Represented by the Department of Veterans Affairs

patents

4. 1 out of 3,381

University of Michigan

patents

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11939291 - GRP94 selective inhibitors and uses thereof (2024-03-26),

2. 11931373 - HSP90 activator AHA1 drives production of pathological tau aggregates (2024-03-19),

3. 11318155 - Hsp90 activator Aha1 drives production of pathological tau aggregates (2022-05-03),

4. 10975030 - Grp94 selective inhibitors and uses thereof (2021-04-13),

5. 10821107 - Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use (2020-11-03),

6. 10814015 - Transgenic mouse model for conditional FKBP51 expression and related methods (2020-10-27),

7. 10358405 - Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases (2019-07-23),

8. 10287227 - Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases (2019-05-14),

9. 9962379 - Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use (2018-05-08),

10. 9808448 - Pharmaceutical compounds and use of same in cancer and tauopathies (2017-11-07),

11. 9598338 - Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases (2017-03-21),

12. 9481864 - Conversion of non-neuronal cells into neurons (2016-11-01),

13. 9399039 - Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use (2016-07-26),

14. 9206103 - Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases (2015-12-08),

15. 9045434 - Compositions and methods of treatment for myocilin glaucoma by selectively inhibiting GRP94 (2015-06-02),

Title: The Innovative Mind of Chad Dickey: Pioneering Research in Cancer and Neurodegenerative Diseases

Introduction: Chad Dickey, a distinguished inventor based in Tampa, FL, has made significant strides in the field of biomedical science with a remarkable portfolio of 16 patents. His innovative work focuses on developing compounds and methods aimed at treating serious conditions such as metastatic cancer and neurodegenerative diseases.

Latest Patents: Among his most recent inventions are the GRP94 selective inhibitors, which provide therapeutic solutions for metastatic cancer and glaucoma. This technology involves compounds described by specific formulas that have shown potential in treating these challenging health issues. Additionally, he has developed patents for inhibiting Aha1, a critical factor in the production of pathological tau aggregates linked to tauopathies and neurodegenerative diseases. These Aha1 inhibitors, which include compounds such as KU-177, KU-174, and KU-308, may reduce tau protein aggregation, opening new avenues for treatment in this field.

Career Highlights: Chad Dickey’s impressive career includes pivotal roles at prestigious institutions such as the University of South Florida and the University of Kansas. His research is not only impactful within academic circles but also bridges the gap between laboratory innovations and practical applications in healthcare.

Collaborations: Throughout his career, Chad has collaborated with esteemed colleagues, including Bill J. Baker and Matthew Lebar. These partnerships reflect a cooperative spirit in advancing scientific research and developing patented technologies that have the potential to change lives.

Conclusion: With a robust foundation of patents and a commitment to innovation, Chad Dickey stands as a leading figure in the fight against cancer and neurodegenerative diseases. His contributions to science through targeted research and collaboration exemplify the power of innovation in addressing some of the most pressing health challenges today.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com